Bootstrap Bio and Manhattan Genomics, two companies focused on human embryo editing to prevent genetic diseases, have ceased operations. The closures mark a setback for the controversial field of germline editing.
Bootstrap Bio and Manhattan Genomics have both shut down their operations, ending their respective efforts to develop human embryo editing technologies. The companies were among a small number of firms pursuing germline editing—modifications to embryos that would be inherited by future generations—primarily to prevent serious genetic conditions.
The reasons behind the closures were not immediately detailed, but the exits underscore the commercial and regulatory challenges facing the embryo editing sector. The field has faced intense scrutiny from bioethicists, policymakers, and the public since Chinese scientist He Jiankui's 2018 announcement of the first gene-edited babies, which triggered global controversy and criminal charges against him.
The U.S. and many other countries have restricted or banned germline editing in humans. While some researchers continue work on somatic gene therapy—editing non-reproductive cells—the commercial viability of human embryo editing remains highly uncertain.
Miles Wang, an OpenAI researcher focused on AI-accelerated scientific discovery, is departing the company to start a new AI drug discovery venture. The startup is in talks to raise $200 million at a $2 billion valuation.
Hadrius, an NYC-based fintech startup, secured $22 million in Series A funding led by CRV with backing from Y Combinator. The company provides AI-native compliance software for financial services firms.
InstaLILY, an enterprise automation startup, has raised $60 million in Series B funding led by Energize Capital, bringing its total funding to nearly $100 million.
Adapter, an infrastructure platform enabling AI agents and applications to leverage and control data, has emerged from stealth with $17.8 million in funding led by GV.